Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

While the company is showing early signs of recovery and margin improvement, a high valuation means risks remain.

Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal ...

BioVaxys Technology Corp. (OTC:BVAXF) issued a comprehensive corporate update, detailing its strategic initiatives. BioVaxys ...

LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput ...